BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Shas threatens to oppose 2026 state budget over haredi food-voucher exclusion - 2Rights group: At least 2,500 deaths during protest crackdown in Iran
- 3Figure out How to Remain Persuaded During Your Internet based Degree Program
- 4My Pioneering Excursion: Building a Startup
- 56 Exceptionally Appraised Summer Travel Objections
- Kremlin: Russian troops conquer Pokrovsk after year of intense combat
- Taco Bell debuts its Baja Blast pie, and the reactions may surprise you
- Spanish bishops and government sign deal for compensation of church sexual abuse victims
- Trump administration launches new immigration crackdowns in New Orleans and Minneapolis. Here are all the cities it has targeted so far.
- Figure out How to Remain Informed about the Most recent Open Record Extra Offers
- Mexico says a third of 130,000 missing people might be alive, fueling criticism from families
- The 15 Most Powerful Forerunners in Business
- Indoor Drinking Fountains: Famous Home Advancements during the Pandemic
- The Fate of Rest: Patterns in Shrewd Beds
